Geode Capital Management’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-43,737
| Closed | -$145K | – | 4248 |
|
|
2019
Q4 | $145K | Hold |
43,737
| – | – | ﹤0.01% | 3899 |
|
|
2019
Q3 | $132K | Hold |
43,737
| – | – | ﹤0.01% | 3887 |
|
|
2019
Q2 | $104K | Buy |
43,737
+23,767
| +119% | +$71K | ﹤0.01% | 3953 |
|
|
2019
Q1 | $74K | Hold |
19,970
| – | – | ﹤0.01% | 3952 |
|
|
2018
Q4 | $71K | Hold |
19,970
| – | – | ﹤0.01% | 3925 |
|
|
2018
Q3 | $114K | Hold |
19,970
| – | – | ﹤0.01% | 3902 |
|
|
2018
Q2 | $100K | Hold |
19,970
| – | – | ﹤0.01% | 3868 |
|
|
2018
Q1 | $102K | Hold |
19,970
| – | – | ﹤0.01% | 3832 |
|
|
2017
Q4 | $120K | Hold |
19,970
| – | – | ﹤0.01% | 3780 |
|
|
2017
Q3 | $110K | Hold |
19,970
| – | – | ﹤0.01% | 3809 |
|
|
2017
Q2 | $92K | Sell |
19,970
-123
| -0.6% | -$549 | ﹤0.01% | 3863 |
|
|
2017
Q1 | $99K | Buy |
20,093
+3,562
| +22% | +$34.3K | ﹤0.01% | 3833 |
|
|
2016
Q4 | $183K | Buy |
16,531
+2,514
| +18% | +$23.7K | ﹤0.01% | 3645 |
|
|
2016
Q3 | $129K | Buy |
14,017
+88
| +0.6% | +$736 | ﹤0.01% | 3737 |
|
|
2016
Q2 | $88K | Sell |
13,929
-24,314
| -64% | -$161K | ﹤0.01% | 3828 |
|
|
2016
Q1 | $249 | Buy |
38,243
+4,574
| +14% | +$29.5K | ﹤0.01% | 3562 |
|
|
2015
Q4 | $273K | Buy |
33,669
+1,483
| +5% | +$11.1K | ﹤0.01% | 3553 |
|
|
2015
Q3 | $235K | Buy |
32,186
+4,254
| +15% | +$43.4K | ﹤0.01% | 3618 |
|
|
2015
Q2 | $286K | Buy |
+27,932
| New | +$309K | ﹤0.01% | 3444 |
|
Geode Capital Management's FOMX Position: Q1 2020 in Review
Geode Capital Management sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q1 2020, closing a stake of 43,737 shares — an estimated $145K sold.
Geode Capital Management first reported a position in FOMX in Q2 2015 and held it in 19 quarters. The position peaked at $286K in Q2 2015. 3 funds tracked by Wall St. Rank hold FOMX as of Q1 2020.
- Geode Capital Management reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q1 2020 after selling out during the quarter.
- Geode Capital Management sold 43,737 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q1 2020, an estimated $145K.
- Geode Capital Management first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q2 2015 and held it in 19 quarters.
- Geode Capital Management's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $286K in Q2 2015.
- 3 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q1 2020.
Based on Geode Capital Management's 13F filing for Q1 2020, filed 14 May 2020.